King & Spalding: Administrative, Congressional, and State Interest Signal a Potential Breakthrough Moment for Psychedelics

In 2024, a workshop cohosted by FDA and the Reagan-Udall Foundation for the FDA (Reagan-Udall) focusing on advancing psychedelic clinical study design. Also in 2024, a second workshop by Reagan-Udall focusing specifically on understanding potential therapeutic uses of ketamine.

Read more